Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benzphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.96 |
| ▸ | HTR2A | P28223 | 1/20 | 0.96 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.96 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.96 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.65 |
| ▸ | MAOB | P27338 | 6/20 | 0.64 |
| ▸ | MAOA | P21397 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | SNCA | P37840 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzphetamine SCHEMBL28360250 | 1.00 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL6272098 | 1.00 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL260091 | 1.00 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL49120 | 0.98 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL19285634 | 0.98 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL678807 | 0.98 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL4329836 | 0.94 | ADRA2B (0.92) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL15388333 | 0.91 | ADRA2B (0.86) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Hydrochloric Acid SCHEMBL9125055 | 0.82 | ADRA2B (0.66) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| SCHEMBL12648381 | 0.82 | SLC6A2 (0.71) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3956 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4654966-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2025-12-03 | — | — | EP | claimed |
| WO-2025137653-A1 | METHODS AND COMPOSITIONS OF POLYCYCLIC AND A DUAL ACTING NITROXIDE COMPOUNDS FOR TREATMENT OF FAT CELL ASSOCIATED DISEASES | MELLICELL, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2024159211-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2024-08-02 | — | — | WO | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-20190127433-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | UNIV INDIANA RES & TECH CORP (US) | 2019-05-02 | — | — | US | claimed |
| US-10174093-B2 | Glucagon/GLP-1 receptor co-agonists | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-01-08 | — | — | US | claimed |
| US-20170349642-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | UNIV INDIANA RES & TECH CORP (US) | 2017-12-07 | — | — | US | claimed |
| US-9758562-B2 | Glucagon/GLP-1 receptor co-agonists | Indiana University and Technology Corporation (US) | 2017-09-12 | — | — | US | claimed |
| CN-105324125-A | Prodrugs with prolonged action | UNIV INDIANA RES & TECH CORP | 2016-02-10 | — | — | CN | claimed |
| WO-2014152460-A2 | PRODRUGS WITH PROLONGED ACTION | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-09-25 | — | — | WO | claimed |
| EP-2487184-A1 | Glucagon/GLP-1 receptor co-agonists | Indiana University Research and Technology Corporation (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2009049105-A2 | METHODS FOR INDUCING SATIATION | GELESIS, INC. (US) | 2009-04-16 | — | — | WO | claimed |
| CN-1795007-A | Methods and compositions for treating gastrointestinal disorders | MICROBIA INC (US) | 2006-06-28 | — | — | CN | claimed |
| EP-1594517-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA INC (US) | 2006-03-29 | — | — | EP | claimed |
| EP-1594517-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Microbia, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040266989-A1 | Methods and compositions for the treatment of gastrointestinal disorders | MICROBIA, INC. | 2004-12-30 | — | — | US | claimed |
| WO-2004069165-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2004-08-19 | — | — | WO | claimed |
| CN-1072863-A | Be used to improve the dermal osmosis system of the reinforcement of medicine localized delivery | RICHARDSON VICKS INC (US) | 1993-06-09 | — | — | CN | claimed |